Clinical TrialCrossoverKetaminePlaceboCompleted

Understanding the Glutamate System in Adults With Obsessive-Compulsive Disorder With N-methyl-D Aspartate Antagonist Ketamine

In this study investigators are studying the effects of a drug called ketamine on the symptoms of Obsessive-compulsive disorder (OCD).

Ask Blossom about this trial
Target Enrollment
15 participants
Study Type
Phase II interventional
Design
Randomized, double Blind

Study Arms & Interventions

Ketamine

experimental

A single 40-minute intravenous infusion of ketamine (0.5 mg/kg) administered while lying supine in an MRI scanner.

Interventions

  • Ketamine0.5 mg/kg
    via IV• single dose• 1 doses total

    Subanesthetic dose administered during a 40-minute infusion.

Saline

placebo

A single 40-minute intravenous infusion of saline administered while lying supine in an MRI scanner.

Interventions

  • Placebo
    via IV• single dose• 1 doses total

    Saline infusion used as a control in a crossover design.

Study Details

  • Status
    Completed
  • Phase
    Phase II
  • Type
    interventional
  • Design
    Randomizeddouble Blind
  • Target Enrollment15 participants
  • Timeline
    Start: 2010-04-01
    End: 2015-12-01
  • Compounds
    KetaminePlacebo

Study Team

Sponsors & Collaborators

Related Publications

Open AccessindividualPrimary

In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: proof of concept

This randomised, placebo-controlled, crossover trial study (n=17) investigates concurrent neurochemical effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder (OCD). It suggested that models of OCD pathology should examine the role of GABAergic abnormalities in OCD symptomatology.

Published
Journal
Psychiatry Research
Authors
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Ogden, R. T., Mao, X., Milak, M. S., Vermes, D., Xie, S., Hunter, L., Flood, P., Moore, H., Shungu, D. C., Simpson, H. B.